Trelegy ellipta and Pulmonary mass - a phase IV clinical study of FDA data

Summary:

Pulmonary mass is reported as a side effect among people who take Trelegy ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Gabapentin, and have Chronic obstructive pulmonary disease.

The phase IV clinical study analyzes which people have Pulmonary mass when taking Trelegy ellipta. It is created by eHealthMe based on reports of 27,966 people who have side effects when taking Trelegy ellipta from the FDA, and is updated regularly.

What is Trelegy ellipta?

Trelegy ellipta has active ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 28,101 Trelegy ellipta users. Check the latest studies of Trelegy ellipta.

What is Pulmonary mass?

Pulmonary mass is found to be associated with 1,138 drugs and 920 conditions by eHealthMe. Check the latest studies of Pulmonary mass.

On Jul, 15, 2026

27,966 people reported to have side effects when taking Trelegy ellipta.
Among them, 91 people (0.33%) have Pulmonary mass.

Could Trelegy ellipta cause Pulmonary mass?

Among these 91 people:

How long have people been on Trelegy ellipta when they have Pulmonary mass? *

What is the gender of people who have Pulmonary mass when taking Trelegy ellipta? *

female: 48.81 %
male: 51.19 %

What is the age of people who have Pulmonary mass when taking Trelegy ellipta? *

What are other drugs people take besides Trelegy ellipta? *

What are other side effects people have besides Pulmonary mass? *

Dyspnea (difficult or laboured breathing): 29 people, 31.87%
Pneumonia: 21 people, 23.08%
Fatigue (feeling of tiredness): 20 people, 21.98%
Cough: 18 people, 19.78%
Wheezing (a high-pitched whistling sound made while you breath): 17 people, 18.68%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 15 people, 16.48%
Headache (pain in head): 15 people, 16.48%
Anaemia (lack of blood): 13 people, 14.29%
Coughing Up Blood: 13 people, 14.29%
Pain: 12 people, 13.19%

What are the existing conditions these people have? *

Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 29 people, 31.87%
Stress And Anxiety: 11 people, 12.09%
Constipation: 8 people, 8.79%
Dyspnea (difficult or laboured breathing): 8 people, 8.79%
Asthma: 7 people, 7.69%
Immunodeficiency Common Variable: 7 people, 7.69%
High Blood Cholesterol: 7 people, 7.69%
Nausea (feeling of having an urge to vomit): 6 people, 6.59%
Multifocal Motor Neuropathy (a progressively worsening condition where muscles in the extremities gradually weaken): 6 people, 6.59%
Iron Deficiency: 6 people, 6.59%

* Approximation only. Some reports may have incomplete information.

Do you take Trelegy ellipta and have Pulmonary mass?

- Check whether Pulmonary mass is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Trelegy ellipta:

Trelegy ellipta (28,101 reports)

Pulmonary mass treatments and more:

Pulmonary mass (17,472 reports)

How severe was Pulmonary mass and when was it recovered:

Pulmonary mass in Trelegy ellipta

Expand to all the drugs that have ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate:

Pulmonary mass and drugs with ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate (95 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Trelegy ellipta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary mass:

Pulmonary mass (1,138 drugs)

Browse all the conditions that are associated with Pulmonary mass:

Pulmonary mass (920 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fluticasone furoate; umeclidinium bromide; vilanterol trifenatate (the active ingredients of Trelegy ellipta) and Trelegy ellipta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.